Patent Expiries of Leading Respiratory Drugs: 2008 and Beyond
Antipsychotics
Leading Schizophrenia Drugs
Side Effects of Antipsychotics – A Major Issue
Patent Expiries
Patent Expiries of Leading Anti-Psychotic Drugs
Zyprexa Continues to Lose Market Share
Risperdal Sales to Plunge, Following its Patent Expiry
Generics - Yet to Make a Mark in Antipsychotics
Increasing Use of Antipsychotics in Children Raises Concerns
Proton Pump Inhibitors
Patent Expiries of Leading Proton Pump Inhibitors: 2008 and Beyond

Table 17. Development of New Molecular Entities (Biological and Chemical) by Various Region/Country: Percentage Share Breakdown for the Periods 1998-2002 & 2003-2007 (includes corresponding Graph/Chart)

Table 18. Number of Compounds Under Development by Country/Region: Percentage Breakdown for the year 2007 (includes corresponding Graph/Chart)

New Molecular Entities (NMEs) Approved by FDA in 2008
New Biological Entities Approved by FDA in 2008
Research and Development

Table 20. World Demographic Trends: People Over 65 as a Percentage of Total Population by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific, and Latin America for years 2000, 2008, 2010, and 2020 (includes corresponding Graph/Chart)

Prescription Drugs Spending on the Rise
Private Sector Insurance Continues to Gain Popularity
Canadian Prescription Drugs Market- A Comparison with the US
Generic Sales to Outpace Branded Drugs Sales
Generics Market in Canada
Generics to Offer Potential Cost Savings
New Patented Drugs- Adding Costs but Little Value
Two-level Drug Approval Process in Canada
Policy Differences Affect Generic Substitution Among Provinces
Applied and Other Research Take Major Chunk of R&D Investments in Canada

Table 48. Investments in Research & Development in Canada (1998, 2001, 2004 and 2007): Percentage Breakdown by Research Type- Applied Research, Basic Research and Other Research Areas (includes corresponding Graph/Chart)

Current and Future Analysis
Pharmaceutical Spending on the Rise
Mounting Healthcare Bills Boost Generic Drugs Consumption
Biogenerics Foray into Europe
SNRIs Likely to Replace SSRIs
Research and Development

Current and Future Analysis
Overview of Pharmaceutical Industries in Select Countries
India
Competitive Advantage
Number of FDA Approved Plants in India Vis-à-Vis Other Countries
Increasing Disposable Income Driving Consumption of Drugs
Generics to Surge Growth in Exports
Manufacturers Continue to Target Developed Markets
India to Emerge as an Important Pharmaceutical Manufacturing Center
Threat from Other Asian Countries
India to Emerge as a Major Hub for Biogenerics
Acute Therapy Class Leads the Market

Increase in Private Healthcare Services
China
Chinese Pharma Industry Remains Immune to Global Crisis, for Now
Issues and Trends
Pharmaceutical Firms to Play Pivotal Role in Transforming Healthcare System
Brand Name Drugs to Exhibit Fastest Growth, While Generics Continue to Lead
Generics in China
Traditional Medicines – Substantial Share